Increase of Serum Kallikrein-8 Level After Long-term Telbivudine Treatment.

Abstract

BACKGROUND/AIM:

Our previous cDNA microarray study revealed increased cellular mRNA levels of a panel of genes, including kallikrein-8 (KLK8), after long-term telbivudine treatment in chronic hepatitis B patients. The aim of this study was to verify whether serum protein levels of KLK8, a cancer-related enzyme, are indeed increased after telbivudine treatment.

PATIENTS AND METHODS:

A total of 83 chronic hepatitis B patients receiving telbivudine for >2 years were retrospectively analyzed. Serum KLK8 protein and estimated glomerular filtration rate (eGFR) changes were compared before and after treatment.

RESULTS:

Both serum KLK8 protein and eGFR increased significantly after long-term telbivudine treatment (paired t-test: KLK8, p<0.001; eGFR, p=0.001). No direct correlation was found between KLK8 increase and eGFR change. However, eGFR change was positively associated with post-treatment KLK8 levels following adjustment for body height (p<0.001).

CONCLUSION:

Telbivudine treatment resulted in increased levels of serum KLK8 protein. Furthermore, eGFR increase was associated with body height-adjusted, post-treatment KLK8 levels.

• Authors: Haw-En Wang, Chih-Lang Lin, Tai-Long Pan, Chau-Ting Yeh
• Journal: In vivo (Athens, Greece) (In Vivo) 2018 Jul-Aug Vol. 32 Issue 4 Pg. 955-960 ISSN: 1791-7549 [Electronic] Greece
• PMID: 29936485 (Publication Type: Journal Article)
• Copyright: Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Antiviral Agents
• Telbivudine
• KLK8 protein, human
• Kallikreins
• Thymidine

Topics

• Adult
• Antiviral Agents (administration & dosage, adverse effects)
• Female
• Glomerular Filtration Rate
• Hepatitis B, Chronic (blood, drug therapy, pathology)
• Humans
• Kallikreins (blood)
• Male
• Middle Aged
• Telbivudine
• Thymidine (administration & dosage, adverse effects, analogs & derivatives)